The content on this site is intended for healthcare professionals only
Dr Giuseppe Curigliano, speaking at the 2010 ASCO conference: A retrospective study of women with metastatic breast cancer showed that the biological characteristics of their primary tumours - including oestrogen, progesterone, and HER2 status - often changes when the cancer spread to the liver, requiring a change in therapy for many women.
Click here to see an interview with Dr Giuseppe Curigliano on ecancertv from the 11th Milan Breast Cancer Conference 2009.
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC
OncoAlert round up July 28th to August 3rd, 2023
Updates on triple-negative breast cancer and immunotherapy
Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer
